ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE

被引：0
|
作者：
Felip, Enriqueta [1 ]
Hernandez-Losa, Javier [2 ]
Murtra-Garrell, Nuria [1 ]
Freixinos, Victor [1 ]
Salcedo, Maite [2 ]
Tallada, Natalia [2 ]
Teixido, Cristina [2 ]
Martinez, Pablo [1 ]
Cedres, Susana [1 ]
Lopez, Eva [3 ]
Pandielle, Anastasio
Cajal, Santiago Ramon Y. [2 ]
机构：
[1] Vall Hebron Univ Hosp, Dept Oncol, Barcelona, Spain
[2] Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain
[3] Vall Hebron Hosp, Dept Stat, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR mutation; ErbB3;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1104 / S1105
页数：2
相关论文
共 50 条
  • [41] Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutations
    Wang, Mengzhao
    Xu, Yan
    Huang, Wen-Tsung
    Su, Wu-Chou
    Gao, Bo
    Lee, Chee Khoon
    Fang, Jian
    Zhu, Xuehua
    Yang, Zhenfan
    Jaenne, Pasi A.
    Yang, James Chih-Hsin
    LUNG CANCER, 2025, 199
  • [42] Combination effects of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and individual chemotherapeutics in non-small cell lung cancer (NSCLC) cells with and without sensitizing-EGFR mutations
    Tsai, C.
    Chang, K.
    Chiu, C.
    Hsiao, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [43] Effect of uncommon and insensitive mutation on EGFR-TKI in treatment of non-small cell lung cancer.
    Zhang, Hui
    Jiang, Da
    Wei, Suju
    Cui, Yanzhi
    Li, Ying
    Tian, Caijuan
    Dong, Qian
    Xu, Zanmei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Investigation of AKT3 in the resistance of non-small cell lung cancer to EGFR-TKI
    Huang, Shih-Hsiang
    Shih, Jin-Yuan
    Chen, Ching-Chow
    CANCER RESEARCH, 2019, 79 (13)
  • [45] EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC) with EGFR activating mutations - real world data
    Dulloo, Sean
    Almusarhed, Manar
    Chen, Ryan
    Akala, Oyeyemi
    Varadhan, Balaji
    Chauhan, Meera
    Ahmed, Samreen
    LUNG CANCER, 2021, 156 : S40 - S40
  • [46] Efficacy and safety of epidermal growth factor receptor (EGFR) - Tyrosine kinase inhibitors (TKI) in elderly patients with EGFR mutation-positive non-small cell lung cancer (NSCLC)
    Takeyasu, Y.
    Goto, Y.
    Morita, R.
    Sato, J.
    Murakami, S.
    Horinouchi, H.
    Fujiwara, Y.
    Kanda, S.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
    Thang Thanh Phan
    Bich-Thu Tran
    Son Truong Nguyen
    Toan Trong Ho
    Hang Thuy Nguyen
    Vu Thuong Le
    Anh Tuan Le
    CLINICAL AND TRANSLATIONAL MEDICINE, 2019, 8
  • [48] Chemotherapeutic agents and the EGFR-TKI osimertinib provoke calreticulin exposure in non-small cell lung cancer
    Inoue, Hiroyuki
    Furukawa, Rie
    Yoneshima, Yasuto
    Tsutsumi, Hirono
    Iwama, Eiji
    Ikematsu, Yuki
    Ando, Nobuhisa
    Shiraishi, Yoshimasa
    Ota, Keiichi
    Tanaka, Kentaro
    Okamoto, Isamu
    RESPIROLOGY, 2023, 28 : 305 - 305
  • [49] The efficacy and safety of EGFR-TKI combined with chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR co-mutation with other oncogenic alterations.
    Yu, Qitao
    Jiang, Wei
    Zeng, Aiping
    Qiu, Hongtu
    Qi, Chuang
    Zhang, Xing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345